PKN605
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 02, 2026
A Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Subjects With Normal Renal Function
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New P1 trial • Renal Disease
February 18, 2026
CPKN605A12201: A study to investigate the efficacy, safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation
(clinicaltrialsregister.eu)
- P1/2 | N=41 | Recruiting | Sponsor: Novartis Pharma AG
New P1/2 trial • Atrial Fibrillation • Cardiovascular
November 22, 2025
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
(clinicaltrials.gov)
- P2 | N=165 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Atrial Fibrillation • Cardiovascular
October 17, 2025
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
(clinicaltrials.gov)
- P2 | N=165 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New P2 trial • Atrial Fibrillation • Cardiovascular
1 to 4
Of
4
Go to page
1